I think further htert sales (ie china), exosome revenue news, some sort of resolution to the court case would be good/great and failing that by the middle of 2022 an announcement about a partnership with a large US partner to run subb2m clincal trials will really bring this company out of speculative biotech status to a commercial reality as a cancer diagnostic with a world beating product. These are just some of the things they have laid out in previous announcements.
I think further htert sales (ie china), exosome revenue news,...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.30M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 46.0¢ | 45.5¢ | $41.74K | 91.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18000 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 1195 | 1 |
View Market Depth
| Last trade - 14.32pm 01/11/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |